Clinical responses to EGFR-tyrosine kinase inhibitor retreatment in non-small cell lung cancer patients who benefited from prior effective gefitinib therapy: A retrospective analysis

BMC Cancer

Volumn 11, Issue , 2011, Pages

  Watanabe, Satoshi ^a   Tanaka, Junta ^a   Ota, Takeshi ^a   Kondo, Rie ^a   Tanaka, Hiroshi ^a   Kagamu, Hiroshi ^a   Ichikawa, Kosuke ^a   Koshio, Jun ^a   Baba, Junko ^a   Miyabayashi, Takao ^a   Narita, Ichiei ^a   Yoshizawa, Hirohisa ^a  

^a NIIGATA UNIVERSITY MEDICAL AND DENTAL HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; GEFITINIB; PROTEIN KINASE INHIBITOR; QUINAZOLINE DERIVATIVE;

ADULT; AGED; ARTICLE; CANCER CONTROL; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; DIARRHEA; DISEASE COURSE; DRUG EFFICACY; DRUG RESPONSE; DRUG TREATMENT FAILURE; FEMALE; GENE MUTATION; HUMAN; INTERSTITIAL LUNG DISEASE; LIVER DISEASE; LUNG NON SMALL CELL CANCER; MALE; NAIL DISEASE; NAUSEA; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; RASH; RETREATMENT; RETROSPECTIVE STUDY; SIDE EFFECT; SURVIVAL TIME; TASTE; TUMOR GROWTH; CHEMICALLY INDUCED DISORDER; DRUG ANTAGONISM; KAPLAN MEIER METHOD; LUNG TUMOR; MIDDLE AGED; TREATMENT OUTCOME;

AGED; CARCINOMA, NON-SMALL-CELL LUNG; DIARRHEA; EXANTHEMA; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; MALE; MIDDLE AGED; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RETREATMENT; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 78650660439     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-11-1     Document Type: Article

References (45)

1. Fukuoka M, Yano S, Giaccone G, Tamura T, Nakagawa K, Douillard JY, Nishiwaki Y, Vansteenkiste J, Kudoh S, Rischin D, Eek R, Horai T, Noda K, Takata I, Smit E, Averbuch S, Macleod A, Feyereislova A, Dong RP, Baselga J. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected]. J Clin Oncol 2003, 21:2237-2246. 10.1200/JCO.2003.10.038, 12748244.
2. Kris MG, Natale RB, Herbst RS, Lynch TJ, Prager D, Belani CP, Schiller JH, Kelly K, Spiridonidis H, Sandler A, Albain KS, Cella D, Wolf MK, Averbuch SD, Ochs JJ, Kay AC. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA 2003, 290:2149-2158. 10.1001/jama.290.16.2149, 14570950.
3. Kim ES, Hirsh V, Mok T, Socinski MA, Gervais R, Wu YL, Li LY, Watkins CL, Sellers MV, Lowe ES, Sun Y, Liao ML, Osterlind K, Reck M, Armour AA, Shepherd FA, Lippman SM, Douillard JY. Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial. Lancet 2008, 372:1809-1818. 10.1016/S0140-6736(08)61758-4, 19027483.
4. Thatcher N, Chang A, Parikh P, Rodrigues Pereira J, Ciuleanu T, von Pawel J, Thongprasert S, Tan EH, Pemberton K, Archer V, Carroll K. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 2005, 366:1527-1537. 10.1016/S0140-6736(05)67625-8, 16257339.
5. Chang GC, Tsai CM, Chen KC, Yu CJ, Shih JY, Yang TY, Lin CP, Hsu JY, Chiu CH, Perng RP, Yang PC, Yang CH. Predictive factors of gefitinib antitumor activity in East Asian advanced non-small cell lung cancer patients. J Thorac Oncol 2006, 1:520-525. 10.1097/01243894-200607000-00004, 17409911.
6. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG, Louis DN, Christiani DC, Settleman J, Haber DA. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004, 350:2129-2139. 10.1056/NEJMoa040938, 15118073.
7. Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S, Herman P, Kaye FJ, Lindeman N, Boggon TJ, Naoki K, Sasaki H, Fujii Y, Eck MJ, Sellers WR, Johnson BE, Meyerson M. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004, 304:1497-1500. 10.1126/science.1099314, 15118125.
8. Mitsudomi T, Kosaka T, Endoh H, Horio Y, Hida T, Mori S, Hatooka S, Shinoda M, Takahashi T, Yatabe Y. Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence. J Clin Oncol 2005, 23:2513-2520. 10.1200/JCO.2005.00.992, 15738541.
9. Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, Sunpaweravong P, Han B, Margono B, Ichinose Y, Nishiwaki Y, Ohe Y, Yang JJ, Chewaskulyong B, Jiang H, Duffield EL, Watkins CL, Armour AA, Fukuoka M. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009, 361:947-957. 10.1056/NEJMoa0810699, 19692680.
10. Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe H, Gemma A, Harada M, Yoshizawa H, Kinoshita I, Fujita Y, Okinaga S, Hirano H, Yoshimori K, Harada T, Ogura T, Ando M, Miyazawa H, Tanaka T, Saijo Y, Hagiwara K, Morita S, Nukiwa T. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 362:2380-2388. 10.1056/NEJMoa0909530, 20573926.
11. Chang JW, Chou CL, Huang SF, Wang HM, Hsieh JJ, Hsu T, Cheung YC. Erlotinib response of EGFR-mutant gefitinib-resistant non-small-cell lung cancer. Lung Cancer 2007, 58:414-417. 10.1016/j.lungcan.2007.05.018, 17618013.
12. Gridelli C, Maione P, Galetta D, Colantuoni G, Del Gaizo F, Ferrara C, Guerriero C, Nicolella D, Rossi A. Three cases of long-lasting tumor control with erlotinib after progression with gefitinib in advanced non-small cell lung cancer. J Thorac Oncol 2007, 2:758-761. 10.1097/JTO.0b013e3180cc25b0, 17762344.
13. Costa DB, Nguyen KS, Cho BC, Sequist LV, Jackman DM, Riely GJ, Yeap BY, Halmos B, Kim JH, Janne PA, Huberman MS, Pao W, Tenen DG, Kobayashi S. Effects of erlotinib in EGFR mutated non-small cell lung cancers with resistance to gefitinib. Clin Cancer Res 2008, 14:7060-7067. 10.1158/1078-0432.CCR-08-1455, 2596582, 18981003.
14. Cho BC, Im CK, Park MS, Kim SK, Chang J, Park JP, Choi HJ, Kim YJ, Shin SJ, Sohn JH, Kim H, Kim JH. Phase II study of erlotinib in advanced non-small-cell lung cancer after failure of gefitinib. J Clin Oncol 2007, 25:2528-2533. 10.1200/JCO.2006.10.4166, 17577030.
15. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000, 92:205-216. 10.1093/jnci/92.3.205, 10655437.
16. Trotti A, Colevas AD, Setser A, Rusch V, Jaques D, Budach V, Langer C, Murphy B, Cumberlin R, Coleman CN, Rubin P. CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol 2003, 13:176-181. 10.1016/S1053-4296(03)00031-6, 12903007.
17. Yokouchi H, Yamazaki K, Kinoshita I, Konishi J, Asahina H, Sukoh N, Harada M, Akie K, Ogura S, Ishida T, Munakata M, Dosaka-Akita H, Isobe H, Nishimura M. Clinical benefit of readministration of gefitinib for initial gefitinib-responders with non-small cell lung cancer. BMC Cancer 2007, 7:51. 10.1186/1471-2407-7-51, 1838917, 17374153.
18. Yoshimoto A, Inuzuka K, Kita T, Kawashima A, Kasahara K. Remarkable effect of gefitinib retreatment in a patient with nonsmall cell lung cancer who had a complete response to initial gefitinib. Am J Med Sci 2007, 333:221-225. 10.1097/MAJ.0b013e31803b8acb, 17435415.
19. Yano S, Nakataki E, Ohtsuka S, Inayama M, Tomimoto H, Edakuni N, Kakiuchi S, Nishikubo N, Muguruma H, Sone S. Retreatment of lung adenocarcinoma patients with gefitinib who had experienced favorable results from their initial treatment with this selective epidermal growth factor receptor inhibitor: a report of three cases. Oncol Res 2005, 15:107-111.
20. Hashimoto N, Imaizumi K, Honda T, Kawabe T, Nagasaka T, Shimokata K, Hasegawa Y. Successful re-treatment with gefitinib for carcinomatous meningitis as disease recurrence of non-small-cell lung cancer. Lung Cancer 2006, 53:387-390. 10.1016/j.lungcan.2006.05.016, 16824645.
21. Kurata T, Tamura K, Kaneda H, Nogami T, Uejima H, Asai Go G, Nakagawa K, Fukuoka M. Effect of re-treatment with gefitinib ('Iressa', ZD1839) after acquisition of resistance. Ann Oncol 2004, 15:173-174. 10.1093/annonc/mdh006, 14679138.
22. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, Tan EH, Hirsh V, Thongprasert S, Campos D, Maoleekoonpiroj S, Smylie M, Martins R, van Kooten M, Dediu M, Findlay B, Tu D, Johnston D, Bezjak A, Clark G, Santabarbara P, Seymour L. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005, 353:123-132. 10.1056/NEJMoa050753, 16014882.
23. Baselga J, Arteaga CL. Critical update and emerging trends in epidermal growth factor receptor targeting in cancer. J Clin Oncol 2005, 23:2445-2459. 10.1200/JCO.2005.11.890, 15753456.
24. Baselga J, Rischin D, Ranson M, Calvert H, Raymond E, Kieback DG, Kaye SB, Gianni L, Harris A, Bjork T, Averbuch SD, Feyereislova A, Swaisland H, Rojo F, Albanell J. Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types. J Clin Oncol 2002, 20:4292-4302. 10.1200/JCO.2002.03.100, 12409327.
25. Hidalgo M, Siu LL, Nemunaitis J, Rizzo J, Hammond LA, Takimoto C, Eckhardt SG, Tolcher A, Britten CD, Denis L, Ferrante K, Von Hoff DD, Silberman S, Rowinsky EK. Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies. J Clin Oncol 2001, 19:3267-3279.
26. Lee DH, Kim SW, Suh C, Yoon DH, Yi EJ, Lee JS. Phase II study of erlotinib as a salvage treatment for non-small-cell lung cancer patients after failure of gefitinib treatment. Ann Oncol 2008, 19:2039-2042. 10.1093/annonc/mdn423, 2733114, 18644828.
27. Viswanathan A, Pillot G, Govindan R. Lack of response to erlotinib after progression on gefitinib in patients with advanced non-small cell lung cancer. Lung Cancer 2005, 50:417-418. 10.1016/j.lungcan.2005.07.004, 16129510.
28. Sim SH, Han SW, Oh DY, Lee SH, Kim DW, Im SA, Chung DH, Kim TY, Lee JS, Kim YW, Heo DS, Bang YJ. Erlotinib after Gefitinib failure in female never-smoker Asian patients with pulmonary adenocarcinoma. Lung Cancer 2009, 65:204-207. 10.1016/j.lungcan.2008.11.006, 19110337.
29. Garfield DH. Modern treatment of lung cancer: case 2. Response to erlotinib after failure of gefitinib in a patient with advanced non-small-cell lung carcinoma. J Clin Oncol 2005, 23:7738-7740. 10.1200/JCO.2005.02.4471, 16234533.
30. Vasile E, Tibaldi C, Chella A, Falcone A. Erlotinib after failure of gefitinib in patients with advanced non-small cell lung cancer previously responding to gefitinib. J Thorac Oncol 2008, 3:912-914. 10.1097/JTO.0b013e318180275e, 18670311.
31. Wong AS, Soong R, Seah SB, Lim SW, Chuah KL, Nga ME, Chin TM, Soo RA. Evidence for disease control with erlotinib after gefitinib failure in typical gefitinib-sensitive Asian patients with non-small cell lung cancer. J Thorac Oncol 2008, 3:400-404. 10.1097/JTO.0b013e318168c801, 18379359.
32. Zhou ZT, Xu XH, Wei Q, Lu MQ, Wang J, Wen CH. Erlotinib in advanced non-small-cell lung cancer after gefitinib failure. Cancer Chemother Pharmacol 2009, 64:1123-1127. 10.1007/s00280-009-0973-1, 19322567.
33. Wong MK, Lo AI, Lam B, Lam WK, Ip MS, Ho JC. Erlotinib as salvage treatment after failure to first-line gefitinib in non-small cell lung cancer. Cancer Chemother Pharmacol 2009, 65:1023-1028. 10.1007/s00280-009-1107-5, 2946542, 19680652.
34. Van Schaeybroeck S, Karaiskou-McCaul A, Kelly D, Longley D, Galligan L, Van Cutsem E, Johnston P. Epidermal growth factor receptor activity determines response of colorectal cancer cells to gefitinib alone and in combination with chemotherapy. Clin Cancer Res 2005, 11:7480-7489. 10.1158/1078-0432.CCR-05-0328, 16243822.
35. Van Schaeybroeck S, Kyula J, Kelly DM, Karaiskou-McCaul A, Stokesberry SA, Van Cutsem E, Longley DB, Johnston PG. Chemotherapy-induced epidermal growth factor receptor activation determines response to combined gefitinib/chemotherapy treatment in non-small cell lung cancer cells. Mol Cancer Ther 2006, 5:1154-1165. 10.1158/1535-7163.MCT-05-0446, 16731747.
36. Engelman JA, Zejnullahu K, Mitsudomi T, Song Y, Hyland C, Park JO, Lindeman N, Gale CM, Zhao X, Christensen J, Kosaka T, Holmes AJ, Rogers AM, Cappuzzo F, Mok T, Lee C, Johnson BE, Cantley LC, Janne PA. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 2007, 316:1039-1043. 10.1126/science.1141478, 17463250.
37. Bean J, Brennan C, Shih JY, Riely G, Viale A, Wang L, Chitale D, Motoi N, Szoke J, Broderick S, Balak M, Chang WC, Yu CJ, Gazdar A, Pass H, Rusch V, Gerald W, Huang SF, Yang PC, Miller V, Ladanyi M, Yang CH, Pao W. MET amplification occurs with or without T790 M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc Natl Acad Sci USA 2007, 104:20932-20937. 10.1073/pnas.0710370104, 2409244, 18093943.
38. Kobayashi S, Boggon TJ, Dayaram T, Janne PA, Kocher O, Meyerson M, Johnson BE, Eck MJ, Tenen DG, Halmos B. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med 2005, 352:786-792. 10.1056/NEJMoa044238, 15728811.
39. Pao W, Miller VA, Politi KA, Riely GJ, Somwar R, Zakowski MF, Kris MG, Varmus H. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2005, 2:e73. 10.1371/journal.pmed.0020073, 549606, 15737014.
40. Costa DB, Halmos B, Kumar A, Schumer ST, Huberman MS, Boggon TJ, Tenen DG, Kobayashi S. BIM mediates EGFR tyrosine kinase inhibitor-induced apoptosis in lung cancers with oncogenic EGFR mutations. PLoS Med 2007, 4:1669-1679. discussion 1680, 10.1371/journal.pmed.0040315, 2043012, 17973572.
41. Balak MN, Gong Y, Riely GJ, Somwar R, Li AR, Zakowski MF, Chiang A, Yang G, Ouerfelli O, Kris MG, Ladanyi M, Miller VA, Pao W. Novel D761Y and common secondary T790 M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors. Clin Cancer Res 2006, 12:6494-6501. 10.1158/1078-0432.CCR-06-1570, 17085664.
42. Bean J, Riely GJ, Balak M, Marks JL, Ladanyi M, Miller VA, Pao W. Acquired resistance to epidermal growth factor receptor kinase inhibitors associated with a novel T854A mutation in a patient with EGFR-mutant lung adenocarcinoma. Clin Cancer Res 2008, 14:7519-7525. 10.1158/1078-0432.CCR-08-0151, 2596620, 19010870.
43. Yamamoto H, Toyooka S, Mitsudomi T. Impact of EGFR mutation analysis in non-small cell lung cancer. Lung Cancer 2009, 63:315-321. 10.1016/j.lungcan.2008.06.021, 18760859.
44. Nguyen KS, Kobayashi S, Costa DB. Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancers dependent on the epidermal growth factor receptor pathway. Clin Lung Cancer 2009, 10:281-289. 10.3816/CLC.2009.n.039, 2758558, 19632948.
45. Jackman D, Pao W, Riely GJ, Engelman JA, Kris MG, Janne PA, Lynch T, Johnson BE, Miller VA. Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer. J Clin Oncol 28:357-360. 10.1200/JCO.2009.24.7049, 19949011.